Detailed Information

Cited 0 time in webofscience Cited 1 time in scopus
Metadata Downloads

Comparative analysis of the efficacy of angiotensin II receptor blockers for uric acid level change in asymptomatic hyperuricaemia

Authors
Kim, Hun-SungKim, HyunahLee, Sue HyunKim, Ju Han
Issue Date
Dec-2020
Publisher
WILEY
Keywords
ACEI; ARB; irbesartan; losartan; uric acid
Citation
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, v.45, no.6, pp 1264 - 1270
Pages
7
Journal Title
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
Volume
45
Number
6
Start Page
1264
End Page
1270
URI
https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/888
DOI
10.1111/jcpt.13202
ISSN
0269-4727
1365-2710
Abstract
What is known and objective There is much controversy over how angiotensin II receptor blockers (ARB) or angiotensin-converting enzyme inhibitors (ACEI) affect blood uric acid levels. Though ARB is not used to lorcwer the uric acid concentration in the blood, losartan, one of the ARB series, is known to reduce the uric acid concentration in the blood and is a preferred drug for hypertensive patients with gout. However, there is no clear conclusive consideration which ARB should be selected for the patients who have simply increased uric acid concentration, other than gout patients. This research aims to compare the variations of the uric acid concentration in the blood in accordance with the prescription of ACEI or ARB targeting patients who were not diagnosed with gout. Methods This research was conducted on the patients who were, for the first time, prescribed ACEI or ARB for a total of 7 years from January 2009 to December 2015. This study has extracted the uric acid values after between 60 days and 120 days (average 90 days, defined as Visit 1) on the basis of the first prescription date of ACEI or ARB. Results and discussion In this study, ACEI was 17.0% of usage (3787/22 293 patients) and ARB was 83.0% (18 506/22 293 patients). Unlike ACEI (5.91 +/- 0.03 vs 5.86 +/- 0.03 mg/dL,P = .059), ARB showed a statistically significant decrease after 3 months (5.71 +/- 0.01 vs 5.69 +/- 0.01 mg/dL,P = .023). In the case of irbesartan (n = 1530, 6.13 +/- 0.06 mg/dL vs 5.89 +/- 0.05 mg/dL,P < .001) and olmesartan (n = 2719, 5.70 +/- 0.04 mg/dL vs 5.63 +/- 0.03 mg/dL,P = .008), the decrease in the uric acid after 3 months was revealed as statistically significant. In elderly aged over 60 years, only irbesartan (n = 855, 5.75 +/- 0.07 mg/dL vs 5.59 +/- 0.07 mg/dL,P = .006) showed a significant decrease in the uric. When the eGFR was less than 60 mL/min/1.73 m(2), both ACEI (n = 1108, 6.95 +/- 0.07 mg/dL vs 6.73 +/- 0.07 mg/dL,P = .001) and ARB (n = 5280, 6.88 +/- 0.03 vs 6.60 mg/dL +/- 0.03 mg/dL,P < .001) showed a significant decrease in the uric acid. What is new and conclusion Although all types of ACEIs and ARBs are being prescribed with similar purposes, ARB (or ACEI) medication does not have a class effect and has varying effects on uric acid levels. The decreases in uric acid levels were relatively small. ARBs seem to be more advantageous than ACEIs for hyperuricaemia patients without gout who are aiming to maintain uric acid decrease levels. Furthermore, irbesartan can be a good substitute for losartan in view of the fact that at least the uric acid level is not increased.
Files in This Item
Go to Link
Appears in
Collections
약학대학 > 약학부 > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Hyun Ah photo

Kim, Hyun Ah
약학대학 (약학부)
Read more

Altmetrics

Total Views & Downloads

BROWSE